Synonyms: A-301 | ATI-50002 | ATI-502
Compound class:
Synthetic organic
Comment: The chemical structure that was submitted to the WHO for the INN ifidancitinib matches one of the that are claimed as Janus kinase (JAK) inhibitors in Rigel Pharmaceuticals' patent WO2012015972A1 [1]. Structurally ifidancitinib is identical to fosifidancitinib (fosifidancitinib) but without the phosphate group. The closest structural match in the patent is example I-221 but this has deuterium iotopes replacing some of the hydrogens on methylanilino group. This compound has been matched to ATI-502 which was developed as a topical agent for dermatological applications.
|
|
References |
1. Chen Y, Ding P, Heckrodt TJ, Li H, Mcmurtrie DJ, Singh R, Taylor V, Yen R. (2012)
Compositions and methods for inhibition of the JAK pathway. Patent number: WO2012015972A1. Assignee: Rigel Pharmaceuticals. Priority date: 28/07/2010. Publication date: 02/02/2012. |